OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the Translational & ADME Sciences Leadership Group (TALG) in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
March 2021
Pages: 24–27
Citation
When referring to this article, please cite it as H. Einolf ,et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Related Content:
